In a major development in the fight against the opioid epidemic, Purdue Pharma and the Sackler family have agreed to a $7.4 billion settlement with 55 U.S. state attorneys general. The deal holds the Sacklers accountable for their aggressive marketing of opioid medications, notably OxyContin, which fueled the nationwide addiction crisis.

As part of the settlement, the Sacklers will be banned from selling opioids in the U.S. and forced to give up control of Purdue Pharma. The money, set to be paid out over the next 15 years, includes a staggering $6.5 billion coming directly from the Sackler family. The payment schedule starts with $1.5 billion up front, followed by $500 million in each of the first two years, then $400 million by year three. Purdue Pharma itself will also contribute an initial $900 million.

Most of the settlement will go to state, local, and tribal governments to support addiction prevention and recovery efforts. And in a rare move for opioid settlements, $850 million is earmarked specifically for victims and their families - an important recognition of the personal toll the crisis has taken.

The Big Takeaway

While the Sacklers' agreement provides some legal protection, they didn't receive full legal immunity. This means they could still face civil liability in future lawsuits, leaving the door open for more legal battles ahead. If this case is any indication, major settlements are on the horizon as litigation around the opioid crisis continues.